neutrophil-mediated disease
Insmed’s Brinsupri Receives First-Ever FDA Approval for Progressive Lung Disease
Brinsupri; Insmed; FDA approval; non-cystic fibrosis bronchiectasis; bronchiectasis; DPP1 inhibitor; brensocatib; progressive lung disease; neutrophil-mediated disease; first-in-class